Skip to main content

Pinealon vs Humanin

Both Pinealon and Humanin are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.

Pinealon

Evidence C

Pinealon (EDR)

A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.

View full Pinealon profile →

Humanin

Evidence B

Humanin (HN)

A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.

View full Humanin profile →

Side-by-Side

AttributePinealonHumanin
Evidence GradeCB
FDA StatusNot FDA-approved — Russian-origin research peptideNot FDA-approved — mitochondrial-derived peptide research compound
Typical Dose5–10 mg daily for 10–20 days (subcutaneous, cycled)Research range: 0.5–1 mg subcutaneous (rare clinical use)
Clinics Indexed95
Categoriescognitive, longevitymitochondrial, longevity, neuroprotection

Key reported benefits — Pinealon

  • Cognitive function (preclinical)
  • Reduced oxidative damage
  • Sleep/circadian effects

Key reported benefits — Humanin

  • Cytoprotection
  • Anti-amyloid effects
  • Insulin sensitization

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons